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The ability of late pregnancy maternal tests
to predict adverse pregnancy outcomes
associated with placental dysfunction
(specifically fetal growth restriction and
pre-eclampsia): a protocol for a systematic
review and meta-analysis of prognostic
accuracy studies
Melanie Griffin1*, Alexander E. P. Heazell2, Lucy C. Chappell3, Jian Zhao1,4,5 and Deborah A. Lawlor1,4,5
Abstract
Background: Pre-eclampsia and being born small for gestational age are associated with significant maternal and
neonatal morbidity and mortality. Placental dysfunction is a key pathological process underpinning these
conditions; thus, markers of placental function have the potential to identify pregnancies ending in pre-eclampsia,
fetal growth restriction, and the birth of a small for gestational age infant.
Primary objective: To assess the predictive ability of late pregnancy (after 24 weeks’ gestation) tests in isolation or
in combination for adverse pregnancy outcomes associated with placental dysfunction, including pre-eclampsia,
fetal growth restriction, delivery of a SGA infant (more specifically neonatal growth restriction), and stillbirth.
Methods: Studies assessing the ability of biochemical tests of placental function and/or ultrasound parameters in
pregnant women beyond 24 weeks’ gestation to predict outcomes including pre-eclampsia, stillbirth, delivery of a
SGA infant (including neonatal growth restriction), and/or fetal growth restriction will be identified by searching the
following databases: EMBASE, MEDLINE, Cochrane CENTRAL, Web of Science, CINAHL, ISRCTN registry, UK Clinical
Trials Gateway, and WHO International Clinical Trials Portal. Any study design in which the biomarker and
ultrasound scan potential predictors have been assessed after 24 weeks’ gestation but before diagnosis of
outcomes (pre-eclampsia, fetal growth restriction, SGA (including neonatal growth restriction), and stillbirth) will be
eligible (this would include randomized control trials and nested prospective case-control and cohort studies), and
there will be no restriction on the background risk of the population. All eligible studies will be assessed for risk of
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bias using the modified QUADAS-2 tool. Meta-analyses will be undertaken using the ROC models to estimate and
compare test discrimination and reclassification indices to test calibration. Validation will be explored by comparing
consistency across studies.
Discussion: This review will assess whether current published data reporting either a single or combination of tests
in late pregnancy can accurately predict adverse pregnancy outcome(s) associated with placental dysfunction.
Accurate prediction could allow targeted management and possible intervention for high-risk pregnancies,
ultimately avoiding adverse outcomes associated with placental disease.
Systematic review registration: PROSPERO CRD42018107049
Keywords: Pre-eclampsia, Small for gestational age (SGA), Fetal growth restriction (FGR), Neonatal growth
restriction/growth restriction in the newborn (NGR), Stillbirth, Biomarker, Placenta, Ultrasound
Background
Pre-eclampsia and being born small for gestational age
(SGA) are associated with significant maternal, fetal, and
neonatal morbidity and mortality [1–3]. Despite the bur-
den of disease associated with these conditions, in the
UK, there has been little decline in their prevalence over
the past two decades and pre-eclampsia remains a lead-
ing cause of maternal death worldwide [4]. Placental
dysfunction plays a key role in the shared pathophysi-
ology of these conditions [5–8]. Tests of placental func-
tion have been proposed as potential prognostic and
diagnostic tools [9].
Delivery of a SGA infant is commonly defined as a
birth weight under a specified threshold and includes
both constitutionally small and growth-restricted infants,
whereas growth restriction is more specifically defined
as the failure of a fetus or infant to reach their full
growth potential and can be diagnosed antenatally (fetal)
or at birth (neonatal). The relationship between delivery
of a SGA infant and adverse pregnancy outcome is likely
secondary to the contribution of fetal (FGR) and/or neo-
natal growth restriction (NGR) within this group. Identi-
fying growth restriction is complex, and study
definitions vary for this outcome and are frequently mis-
classified. Delivery of a SGA infant is often seen as a
surrogate for FGR and NGR and sometimes incorrectly
used interchangeably with these definitions.
Most studies assessing maternal serum biomarkers of
placental origin (e.g., pregnancy-associated plasma pro-
tein A (PAPP-A), alpha-fetoprotein (AFP)) to predict ad-
verse pregnancy outcomes have tested in the first and/or
second trimesters and have insufficient test accuracy for
clinical use [10–12]. While combining biochemical with
biophysical markers in the first and/or second trimesters
appears to improve predictive ability, current evidence is
insufficient for them to be recommended for use in clin-
ical practice [8, 13–15].
Sampling later in pregnancy could provide greater pre-
dictive accuracy, as this is closer to disease onset (com-
pared to first or second trimester sampling). This is
supported by studies evaluating biomarkers associated
with placental function in the third trimester [16–19].
There is most evidence to support the use of late preg-
nancy maternal tests for the prediction of pre-eclampsia,
e.g., tests based upon placental growth factor (PlGF), but
other studies also report benefits in high-risk and unse-
lected populations for the prediction of delivering a SGA
infant [18, 20]. Screening in late pregnancy using mater-
nal tests to predict stillbirth is limited to a few small
studies, and results are conflicting [20–22].
In an attempt to improve clinical outcomes, by tar-
geted intervention for those at greatest risk, the most
accurate late pregnancy prediction model for adverse
pregnancy outcomes associated with placental dysfunc-
tion must be identified. Systematic reviews and meta-
analyses assessing the predictive ability of late pregnancy
tests (specifically maternal serum biomarkers) for condi-
tions associated with placental dysfunction have not to
date identified any accurate prediction tool whose use is
beneficial in clinical practice [10, 23, 24]. However,
several large studies reporting promising results for bio-
markers in prediction of adverse pregnancy outcomes,
particularly pre-eclampsia, have been published since the
most recent of those previous systematic reviews [16, 17,
19, 20]. The aim of this review is to reevaluate the ability
of late pregnancy tests to predict adverse pregnancy out-
comes associated with placental dysfunction incorporat-
ing recent evidence.
A Cochrane diagnostic test accuracy review of bio-
chemical tests of placental function versus ultrasound
assessment of fetal size for stillbirth and SGA infants has
already been undertaken (AH, lead author). Therefore,
this review will primarily focus on prediction of pre-
eclampsia and fetal and neonatal growth restriction
(FGR and NGR) but will also include a search for any
new studies, published subsequent to the period covered
by the Cochrane review, predicting stillbirth and delivery
of a SGA infant, so that a comprehensive up to date re-
view of all evidence can be provided.
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Objective
The primary objective is to explore the predictive ability
of late pregnancy (after 24 weeks’ gestation) maternal
biochemical tests of placental function (including human
placental lactogen (hPL), soluble fms-like tyrosine
kinase-1 (sFlt-1), placental growth factor (PlGF), sFlt-1:
PlGF ratio), and ultrasound parameters (including esti-
mated fetal weight (EFW), umbilical and uterine artery
Doppler pulsatility index, and amniotic fluid index) in
isolation or in combination for adverse pregnancy out-
comes associated with placental dysfunction, including
pre-eclampsia, FGR, delivery of a SGA infant (more spe-
cifically NGR), and stillbirth.
Methods/design
This protocol has been prospectively registered with
the International Prospective Register of Systematic
Reviews (PROSPERO; CRD42018107049) and will fol-
low the preferred reporting items for systematic re-
view and meta-analysis protocol (PRISMA-P)
guidelines (Additional file 1). This includes details of
inclusion and exclusion criteria, a data extraction tool,
and analytical methods.
Inclusion criteria
To be included, they must explore the use of biochem-
ical tests of placental function and/or ultrasound param-
eters in pregnant women as accurate predictors of key
outcomes. Specifically, studies must:
 Assess biochemical placental function tests and/or
ultrasound parameters after 24 completed weeks’
gestation but before the occurrence of outcomes.
The threshold of 24 weeks’ gestation for the
assessment of the late pregnancy predictor (the
focus of this review) has been selected to facilitate
comparison with data soon to be reported in a
Cochrane review, predicting stillbirth, and delivery
of a SGA infant.
 Evaluate their ability to predict one or more of these
outcomes: pre-eclampsia, stillbirth, FGR, delivery of
a SGA infant (including NGR), diagnosed after the
biomarker, or ultrasound scan measurements have
been assessed.
Studies assessing the predictive accuracy of late preg-
nancy maternal tests have used varying definitions for
SGA, FGR, and NGR. To avoid excluding any potential
studies in this systematic review, studies using any defin-
ition of SGA, FGR, or NGR will be assessed. For analysis,
some studies will be reclassified according to the out-
come measures outlined in this protocol. If any study
definitions differ from those we use in this protocol (see
section on outcome measures), that study data will be
analyzed separately to the main outcome measures.
Any study that fulfills these criteria will be included
(this could for example, include randomized controlled
trials, prospective cohort, or nested prospective case-
control studies). There will be no restriction on the
background risk of the population (i.e., unselected or
high-risk antenatal populations), and studies of women
of any age will be included. Placental function bio-
markers in urine or blood can be measured using any
assay technique and threshold for a positive result. Stud-
ies evaluating the predictive ability of any ultrasound
measurement measured beyond 24 weeks’ gestation will
be included; these could include uterine and/or umbil-
ical artery Doppler pulsatility index, estimated fetal
weight, and amniotic fluid index.
Exclusion criteria
Studies including multifetal pregnancies and pregnancies
complicated by major lethal fetal abnormality identified
during pregnancy will be excluded, as these are inde-
pendent risk factors for the pre-specified outcomes and
it is reasonable to assume that concentrations of bio-
markers would be different due to increased placental
mass in multifetal pregnancies and altered trophoblast
function in aneuploidy. Retrospective case-control and
cross-sectional studies will be excluded.
Outcome measures
The primary outcome measures are pre-eclampsia, fetal
growth restriction (FGR), delivery of a small for gesta-
tional age (SGA) infant (including neonatal growth
restriction (NGR)), and stillbirth, defined as:
I. Pre-eclampsia: New hypertension (> 140/90 mmHg)
presenting after 20 weeks’ gestation and significant
proteinuria (urinary protein:creatinine ratio > 30
mg/mmol or a validated 24-h urine collection > 300
mg protein or urine dipstick reading > 1+) or
maternal organ dysfunction:
a. Renal insufficiency (creatinine > 90 μmol/L)
b. Liver involvement (elevated transaminases to
twice normal concentration for pregnancy and/or
severe right upper quadrant or epigastric pain)
c. Neurological complications (examples include
eclampsia, altered mental status, blindness,
stroke, or more commonly hyperreflexia when
accompanied by clonus, severe headaches when
accompanied by hyperreflexia, persistent visual
scotomata)
d. Hematological complications (thrombocytopenia
platelets < 100,000/μL, DIC, hemolysis) [25]
[note that we will only include pre-eclampsia
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diagnosed after measurement of the predic-
tor—so beyond 24 weeks’ gestation]
Any studies using other definitions of pre-eclampsia
will be considered but analyzed and reported
separately.
II. FGR: Abdominal circumference (AC) or estimated
fetal weight (EFW) < 3rd gestation specific centile
or AC/EFW < 10th gestation specific centile
combined with uterine artery Doppler pulsatility
index (UtAPI) > 95th centile and/or umbilical
artery Doppler pulsatility index (UAPI) > 95th
centile [26]
III. SGA: A birth weight classified as small for
gestational age (SGA) within the study. Study
definitions will be documented if this differs to
birth weight ≤ 10th gestation specific centile, using
population or customized birth weight centiles
IV. NGR: A birth weight ≤ 3rd gestation specific
centile, on population or customized growth charts
or at least 3 out of 5 of the following:
a. Birth weight < 10th centile
b. Head circumference < 10th centile
c. Length < 10th centile
d. Prenatal diagnosis of FGR
e. Maternal pregnancy information (e.g., hypertension
or pre-eclampsia) [27]
V. Stillbirth: An infant born with no signs of life (that
was not a planned termination of pregnancy)
Prior to analysis, studies reporting different labels for
the same definitions as our outcome measures (such as
severe SGA for neonatal growth restriction and intra-
uterine growth restriction for fetal growth restriction)
will be reclassified according to the definitions specified
above.
Any studies that include outcomes assessed before 24
weeks’ gestation will be initially included (i.e., at the full
paper screen stage), and we will attempt to use informa-
tion in the paper and/or from contact with authors to
obtain estimates restricted to outcomes after 24 weeks’
gestation.
Search strategy
A detailed search strategy with no language or date
restrictions will search the following sources:
EMBASE, MEDLINE, Cochrane CENTRAL, Web of
Science, CINAHL, ISRCTN registry, UK Clinical
Trials Gateway, WHO International Clinical Trials
Portal, and specialist abstract and conference proceed-
ing resources (Web of Science Conference Proceed-
ings Citation Index and British Library’s ZETOC). A
draft for the search strategy to be used is detailed in
Additional file 2.
In addition, information on ongoing studies, unpub-
lished research and research reported in the grey litera-
ture will be sought. We will report our search terms as
an appendix to published studies.
Study reviews and appraisals
MG and JZ will independently review the titles and ab-
stracts of all studies identified by the search strategy to
identify potentially relevant studies. Full text versions of
all potentially relevant studies will be sought and inde-
pendently assessed for inclusion by MG and JZ following
the pre-specified inclusion criteria stated in the methods.
If there is disagreement, the opinion of a third review
author (DAL) will be sought. Reasons for study exclu-
sion will be documented.
Data extraction
Data will be extracted independently by MG and JZ
and collected using a customized data collection
form. Recorded data will include participant
characteristics, presence of one or more of our pre-
specified outcome measures (including definitions
used), type of biomarker assay or test combinations
(including thresholds for a positive test), and
processing and storage of samples before use. Data
related to pregnancy outcome but additional to our
pre-specified outcome measures will also be
collected, including mode of delivery, maternal com-
plications, and admission to neonatal intensive care
unit.
Sensitivity and specificity of a prognostic test will be
extracted when available; otherwise, true-positive (TP),
false-positive (FP), true-negative (TN), and false-negative
(FN) counts will be collected. For studies reporting data
using multiple thresholds for a test, a 2 × 2 table of the
above counts will be extracted at each threshold. If sam-
ples are reported at multiple time points within a study,
then each will be considered individually. If these data
are not available, we will extract odds ratios and/or area
under (AUC) receiver operating characteristic (ROC)
curves. If study data, critical to our proposed analysis, is
unclear or absent, the relevant authors will be contacted
for clarification.
The risk of bias in each study will be evaluated
using the modified QUADAS-2 tool [28]. Two review
authors (MG and JZ) will independently assess each
study and assign either “yes,” “no,” or “unclear” to
each of the criteria stated in the modified QUADAS-
2 tool. This information will be summarized graphic-
ally in the final review document. Studies will not be
excluded from the main meta-analysis on the basis of
risk of bias.
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Statistical analysis
For those studies where a 2 × 2 table can be extracted,
test specific sensitivity will be calculated as TP/(TP +
FN) and specificity will be calculated as TN/(TN + FP).
Sensitivity will be plotted against specificity to construct
separate receiver operating characteristic (ROC) curves
for each primary outcome to determine test discrimin-
ation and assess for heterogeneity. A hierarchical
summary ROC (HSROC) model will be used to pool the
results to estimate summary sensitivity and specificity
with associated confidence intervals and a ROC curve
[29–31]. The HSROC model takes account of both the
within- and between-study variability by inclusion of a
study specific random effect that allows for heterogen-
eity between studies. If a study reports multiple test
thresholds, the data related to the most frequently
reported threshold across all studies will be included in
the meta-analysis. We will explore the use of more
advanced methodology, which allows pooling of multiple
points per study [32, 33]. We will calculate net reclassifi-
cation in each study as a measure of calibration and pool
these using appropriate methods for proportions [34].
When test specific sensitivity and specificity data or a 2
× 2 table data are not available, we will perform meta-
analysis of odds ratios and/or AUC [35].
Exploration of heterogeneity
We will quantify the amount of heterogeneity using the
between studies standard deviation in logit sensitivity
and logit specificity. If sufficient data are available, we
will explore potential sources of heterogeneity using
subgroup analyses/meta-regression. Key study character-
istics that we intend to explore include risk of bias, study
design, and population characteristics.
Once we have completed the systematic review and
initial summary of completed studies, we will update this
protocol in relation to these subgroup analyses. All stat-
istical analysis will be carried out in the statistical pack-
age Stata version 14 (College Station, TX, USA).
Discussion
This review will provide essential data necessary to
evaluate the ability of late pregnancy tests in isolation
and combination to predict adverse pregnancy outcomes
related to placental dysfunction. It will be the first
comprehensive review of late pregnancy tests, including
ultrasound parameters to predict adverse pregnancy
outcomes, including pre-eclampsia and fetal growth
restriction. This work will build on a Cochrane review
assessing the diagnostic accuracy of biochemical tests of
placental function versus ultrasound assessment of fetal
size for stillbirth and SGA infants and will allow us to
extend their findings to include data relating to pre-
eclampsia and FGR prediction and assess additional data
on delivery of the SGA infant and stillbirth, published
subsequent to the timeframe of that review.
These conditions remain a significant global cause of
maternal and neonatal morbidity and mortality. Identify-
ing an accurate predictive tool using either a single or
combination of tests in late pregnancy would allow
targeted management and possible intervention for
high-risk pregnancies, ultimately avoiding adverse out-
comes associated with placental disease.
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